• KOL
    • KOLs Community
    • Fanconi
    • Fanconi Anemia
    • Mariko Dawn Dewire
    • Mariko Dawn DeWire

      Mariko Dawn DeWire

      Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA | Brain Tumor Center, Division of Oncology, ...



      KOL Resume for Mariko Dawn DeWire


      Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA

      Department of Pediatrics College of Medicine, Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute, University of Cincinnati, Cincinnati, Ohio


      Brain Tumor Center, Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

      Cincinnati Children's Hospital Medical Center, Cincinnati, OH;


      Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA


      Division of Oncology (J.L.A., R.M., N.O., A.L., S.S., R.D., M.F., L.M.C., L.H., M.D., B.D.), Experimental Hematology and Cancer Biology (R.R.W., J.W.), Pathology (L.M.), Developmental Biology, Center for Autoimmune Genomics and Etiology and Biomedical Informatics, Cincinnati Childrens Hospital Medical Center (CCHMC), Cincinnati, Ohio (M.L.W.); Division of Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland (E.H.R.), Nemours Children’s Hospital, Orlando, Florida (L.M.)

      Brain Tumor Center, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, 45229, Cincinnati, OH, USA


      Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229 USA


      Division of Oncology, Hematology/Oncology Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, MLC 7015, 3333 Burnet Avenue, 45225, Cincinnati, OH, USA

      Cincinnati Children's Hospital Medical Center, Cincinnati, OH


      Cincinnati Children's Hospital Medical Center Division of Oncology Cincinnati Ohio


      Authors' Affiliations: Center for Childhood Cancer & Blood Diseases, Nationwide Children's Hospital; Center for Biostatistics, The Ohio State University, Columbus, Ohio; Institut of Pathology, Department Neuropathology, Ruprecht-Karls University and Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany; and Astrazeneca Ltd., Oncology iMed, Macclesfield, United Kingdom


      St Jude Children's Research Hospital, Memphis, TN University of Tennessee Health Science Center, Memphis, TN St Jude Children's Research Hospital, Memphis, TN


      2Department of Oncology, Division of Neurooncology, St. Jude Children's Research Hospital, Memphis, Tennessee


      Dept. of Oncology St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA


      Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee



      Mariko Dawn DeWire: Influence Statistics

      Sample of concepts for which Mariko Dawn DeWire is among the top experts in the world.
      Concept World rank
      dipg bmi1 #7


      Prominent publications by Mariko Dawn DeWire

      KOL-Index: 10057

      PURPOSE: The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244). In this study, we developed and characterized selumetinib resistance and explored approaches to circumventing the mechanisms of acquired resistance.

      EXPERIMENTAL DESIGN: BT-40 xenografts were selected in vivo for selumetinib resistance. Resistant tumors were obtained and characterized, as were tumors that reverted to ...

      Known for Childhood Astrocytoma | Acquired Resistance | Inhibitor Selumetinib | Map Kinase Kinase | Cell Tumor
      KOL-Index: 9510

      OBJECT: Brain tumors in infants are often large, high grade, and vascular, making complete resection difficult and placing children at risk for neurological complications and excessive blood loss. Neoadjuvant chemotherapy may reduce tumor vascularity and volume, which can facilitate resection. The authors evaluated how an ongoing institutional prospective chemotherapy trial would affect patients who did not have a gross-total resection (GTR) immediately and who therefore required further ...

      Known for Neoadjuvant Chemotherapy | Brain Tumors | Subtotal Resection | Tumor Vascularity | Blood Loss
      KOL-Index: 8464

      INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) and midline high-grade glioma (mHGG) are lethal childhood brain tumors. Spatial genomic heterogeneity has been well-described in adult HGG but has not been comprehensively characterized in pediatric HGG. We performed whole exome sequencing on 38-matched primary, contiguous, and metastatic tumor sites from eight children with DIPG (n = 7) or mHGG (n = 1) collected using a unique MRI-guided autopsy protocol. Validation was performed ...

      Known for Diagnostic Biopsy | Grade Glioma | Spatial Genomic Heterogeneity | Diffuse Intrinsic Pontine | Targeted Therapeutics
      KOL-Index: 7919

      Understanding the biology that underlies histologically similar but molecularly distinct subgroups of cancer has proven difficult because their defining genetic alterations are often numerous, and the cellular origins of most cancers remain unknown. We sought to decipher this heterogeneity by integrating matched genetic alterations and candidate cells of origin to generate accurate disease models. First, we identified subgroups of human ependymoma, a form of neural tumour that arises ...

      Known for Driver Mutations | Species Genomics | Central Nervous | Subgroups Ependymoma | Neoplastic Genes
      KOL-Index: 7199

      Background: Diffuse intrinsic pontine glioma (DIPG) is a high-grade brainstem glioma of children with dismal prognosis. There is no single unifying model about the cell of origin of DIPGs. Proliferating cells in the developing human and mouse pons, the site of DIPGs, express neural stem/progenitor cell (NPC) markers, including Sox2, nestin, vimentin, Olig2, and glial fibrillary acidic protein, in an overlapping and non-overlapping manner, suggesting progenitor cell heterogeneity in the ...

      Known for Olig2 Dipg | Pontine Glioma | Dismal Prognosis | Diffuse Intrinsic | Stem Neoplasms
      KOL-Index: 6928

      There is a paucity of data regarding patterns of progression in children with high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) treated with bevacizumab (BVZ) at diagnosis. We performed a retrospective study of 20 children with HGG or DIPG who received BVZ-based therapy at diagnosis on, or according to, a bi-institutional study. Magnetic resonance imaging (MRI) characteristics of first and most recent progressions were reviewed. Comparison was made to a control group of ...

      Known for Pediatric Patients | Hgg Dipg | Glioma Treated | Intrinsic Pontine | Bevacizumab Brain
      KOL-Index: 6540

      Children with high-grade glioma, including diffuse intrinsic pontine glioma (DIPG), have a poor prognosis despite multimodal therapy. Identifying novel therapeutic targets is critical to improve their outcome. We evaluated prognostic roles of telomere maintenance mechanisms in children with HGG, including DIPG. A multi-institutional retrospective study was conducted involving 50 flash-frozen HGG (35 non-brainstem; 15 DIPG) tumors from 45 children (30 non-brainstem; 15 DIPG). Telomerase ...

      Known for Telomere Maintenance Mechanisms | Hgg Dipg | Grade Glioma | Telomerase Activity | Htert Expression
      KOL-Index: 6470

      Although bevacizumab has not proven effective in adults with newly diagnosed high-grade gliomas (HGG), feasibility in newly diagnosed children with diffuse intrinsic pontine gliomas (DIPG) or HGG has not been reported in a prospective study. In a safety and feasibility study, children and young adults with newly diagnosed HGG received radiotherapy (RT) with bevacizumab (10 mg/kg: days 22, 36) and temozolomide (75–90 mg/m2/day for 42 days) followed by bevacizumab (10 mg/kg, days 1, 15), ...

      Known for Grade Gliomas | Intrinsic Pontine | Bevacizumab Dipg | 2 Patients | Glioma Humans
      KOL-Index: 6095

      PURPOSE: Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric disease, with a median survival of <1 year. Here, we review our institution's DIPG experience over an 8-year interval and perform a systematic review of the literature, specifically evaluating reports of reirradiation (reRT) for DIPG.

      METHODS AND MATERIALS: We retrospectively reviewed the medical records of 26 patients who underwent definitive intensity modulated radiation therapy (IMRT) for DIPG at a single ...

      Known for Patients Dipg | Intrinsic Pontine | Radiation Therapy | Single Institution | Progressionfree Survival
      KOL-Index: 5924

      Medulloblastoma, the most common pediatric malignant brain tumor often arises sporadically; however, in a subgroup of patients, there exist familial conditions such as Fanconi anemia with biallelic BRCA2 mutation that predispose patients to developing medulloblastoma. Biallelic inactivation of BRCA2 in Fanconi anemia has been previously described in only 11 patients with medulloblastoma in the literature to date. Here we report two siblings diagnosed with central nervous system embryonal ...

      Known for Fanconi Anemia | Brca2 Mutation | Biallelic Inactivation | Reported Case | Genetic Predisposition
      KOL-Index: 5495

      Pediatric high-grade gliomas (pHGGs) are aggressive neoplasms representing approximately 20% of brain tumors in children. Current therapies offer limited disease control, and patients have a poor prognosis. Empiric use of targeted therapy, especially at progression, is increasingly practiced despite a paucity of data regarding temporal and therapy-driven genomic evolution in pHGGs. To study the genetic landscape of pHGGs at recurrence, we performed whole exome and methylation analyses on ...

      Known for Temporal Genomic Heterogeneity | Grade Gliomas | Brain Tumors | Distinct Subgroups | Genetic Alterations
      KOL-Index: 4338

      BACKGROUND: Female survivors of central nervous system (CNS) tumors are at an increased risk for gonadal damage and variations in the timing of puberty following radiotherapy and alkylating agent-based chemotherapy.

      PROCEDURE: Clinical and laboratory data were obtained from 30 evaluable female patients with newly diagnosed embryonal CNS tumors treated on a prospective protocol (SJMB 96) at St. Jude Children's Research Hospital (SJCRH). Pubertal development was evaluated by Tanner ...

      Known for Ovarian Insufficiency | Brain Tumors | Craniospinal Irradiation | Female Survivors | Neoplasms Child
      KOL-Index: 3468

      Diffuse intrinsic pontine glioma (DIPG) is a poor-prognosis pediatric brain tumor. No effective curative therapy is currently available and no therapeutic advances have been made in several decades. BMI-1 is a member of the multimeric protein complex Polycomb repressor complex 1. It is highly expressed in a number of diseases and malignancies and has been implicated in self-renewal of normal and cancer cells, and in DNA damage signaling. The role of BMI-1 in DIPG is largely unknown. ...

      Known for Diffuse Intrinsic | Pontine Glioma | Dipg Cells | Dna Damage | Cell Cycle
      KOL-Index: 3284

      Pediatric tectal plate gliomas are indolent slow-growing gliomas that often present with increased intracranial pressure or incidentally on routine brain imaging. We investigated clinical outcomes, endocrinopathies, and neuropsychological sequelae associated with tectal plate gliomas. Twenty-six patients with tectal plate glioma were identified in a 20-year retrospective review. Clinical outcomes, treatments, endocrine function, neuropsychological testing outcomes and radiographic ...

      Known for Tectal Plate | Increased Intracranial Pressure | Precocious Puberty | Follow Studies | Tumor Progression
      KOL-Index: 3075

      PurposeCyclin-dependent kinase-retinoblastoma (CDK-RB) pathway is dysregulated in some diffuse intrinsic pontine gliomas (DIPG). We evaluated safety, feasibility, and early efficacy of the CDK4/6-inhibitor ribociclib, administered following radiotherapy in newly-diagnosed DIPG patients.MethodsFollowing radiotherapy, eligible patients received ribociclib in 28-day cycles (350 mg/m2; 21 days on/7 days off). Feasibility endpoints included tolerability for at least 6 courses, and a less than ...

      Known for Diffuse Intrinsic | Pontine Glioma | Hematological Toxicity | Cdk4 6 | Dependent Kinase

      Key People For Fanconi Anemia

      Top KOLs in the world
      Arleen D Auerbach
      fanconi anemia prenatal diagnosis cord blood
      Hans Joenje
      fanconi anemia dna damage cell lines
      Alan D D'Andrea
      fanconi anemia dna repair erythropoietin receptor
      Markus Grompe
      fanconi anemia stem cells gene therapy
      Johan P de Winter
      fanconi anemia activin type core complex
      Detlev Schindler
      fanconi anemia ataxia telangiectasia dna repair

      Mariko Dawn DeWire:Expert Impact

      Concepts for whichMariko Dawn DeWirehas direct influence:Fanconi anemia,  Grade glioma,  Grade gliomas,  Intrinsic pontine,  Pontine glioma,  Diffuse intrinsic,  Diagnostic biopsy,  Dipg hgg.

      Mariko Dawn DeWire:KOL impact

      Concepts related to the work of other authors for whichfor which Mariko Dawn DeWire has influence:Brain tumors,  Intrinsic pontine,  Neoadjuvant chemotherapy,  Diffuse midline glioma,  Fanconi anemia,  Spinal ependymomas,  Pediatric patients.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA | Brain Tumor Center, Division of Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH USA | Department

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.